FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting roche.com
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions roche.com
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer roche.com
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) roche.com
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics roche.com
